Skip to main content

Table 3 Correlations between downregulation of NEARS and poor prognostic factors in clinical prostate tumors

From: Polycomb-mediated silencing in neuroendocrine prostate cancer

Clinical parameters associated with NEARS
Analysis Concept Dataset Odds ratio P value Percentile Samples
vs Met Metastasis Lapointe Prostate 2.4 1.3E-04 Top 10% 71
Metastasis LaTulippe Prostate 2.4 4.5E-04 Top 10% 32
Metastasis Yu Prostate 3.5 2.0E-07 Top 10% 88
Metastasis Grasso Prostate 3.8 5.6E-13 Top 10% 94
Metastasis Vanaja Prostate 4.6 8.4E-18 Top 10% 32
Metastasis Taylor Prostate 3 6.0 2.0E-26 Top 10% 150
Grade Advanced Gleason Score Wallace Prostate 2.2 3.4E-04 Top 10% 65
Advanced Gleason Score Vanaja Prostate 2.4 6.6E-06 Top 10% 27
Advanced Gleason Score Lapointe Prostate 3.4 1.8E-05 Top 5% 61
Advanced Gleason Score Tomlins Prostate 3.6 1.9E-08 Top 10% 30
Advanced Gleason Score Taylor Prostate 3 3.6 4.4E-08 Top 5% 130
Advanced Gleason Score Yu Prostate 4.4 4.1E-07 Top 5% 61
Advanced Gleason Score Setlur Prostate 7.6 2.8E-04 Top 1% 353
High Grade Bittner Prostate 2.5 3.3E-04 Top 5% 46
Outcome Dead at 3 years Setlur Prostate 2.4 2.0E-03 Top 10% 358
Recurrence at 5 years Taylor Prostate 3 3.1 1.3E-09 Top 10% 61
Recurrence at 3 years Taylor Prostate 3 3.5 1.0E-11 Top 10% 107
Recurrence at 5 years Nakagwa Prostate 10.1 1.0E-03 Top 10% 592
Dead at 5 years Setlur Prostate 10.7 2.9E-06 Top 1% 363
Recurrence at 3 years Nakagwa Prostate 15.2 7.9E-04 Top 5% 594